Opus Genetics/$IRD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Ticker
$IRD
Sector
Primary listing
Employees
28
Headquarters
Website
Opus Genetics Metrics
BasicAdvanced
$327M
-
-$0.80
0.59
-
Price and volume
Market cap
$327M
Beta
0.59
52-week high
$5.30
52-week low
$0.65
Average daily volume
1.1M
Financial strength
Current ratio
6.432
Quick ratio
6.202
Long term debt to equity
7.356
Total debt to equity
7.356
Interest coverage (TTM)
-26.33%
Profitability
EBITDA (TTM)
-38.546
Gross margin (TTM)
-117.05%
Net profit margin (TTM)
-349.33%
Operating margin (TTM)
-271.90%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-55.39%
Return on equity (TTM)
-242.41%
Valuation
Price to revenue (TTM)
20.118
Price to book
20.9
Price to tangible book (TTM)
20.9
Price to free cash flow (TTM)
-8.101
Free cash flow yield (TTM)
-12.34%
Free cash flow per share (TTM)
-0.567
Growth
Revenue change (TTM)
29.15%
Earnings per share change (TTM)
-62.99%
3-year revenue growth (CAGR)
-29.11%
3-year earnings per share growth (CAGR)
-2.88%
What the Analysts think about Opus Genetics
Analyst ratings (Buy, Hold, Sell) for Opus Genetics stock.
Opus Genetics Financial Performance
Revenues and expenses
Opus Genetics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Opus Genetics stock?
Opus Genetics (IRD) has a market cap of $327M as of March 24, 2026.
What is the P/E ratio for Opus Genetics stock?
The price to earnings (P/E) ratio for Opus Genetics (IRD) stock is 0 as of March 24, 2026.
Does Opus Genetics stock pay dividends?
No, Opus Genetics (IRD) stock does not pay dividends to its shareholders as of March 24, 2026.
When is the next Opus Genetics dividend payment date?
Opus Genetics (IRD) stock does not pay dividends to its shareholders.
What is the beta indicator for Opus Genetics?
Opus Genetics (IRD) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.